Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"ImmunoBrain Checkpoint","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoBrain Checkpoint Awarded Alzheimer\u2019s Association Grant to Support Phase II Trial Investigating Novel Immunotherapeutic Approach to Treat Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ImmunoBrain Checkpoint"}]

ImmunoBrain Checkpoint

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ImmunoBrain Checkpoint Awarded Alzheimer’s Association Grant to Support Phase II Trial Investigating Novel Immunotherapeutic Approach to Treat Alzheimer’s Disease

Details:

The grant will phase 1 clinical trial to examine safety and activity of its proprietary antibody, IBC-Ab002, targeted to enhance the immune system and induce brain repair processes in individuals with Alzheimer’s disease.

Lead Product(s): IBC-Ab002

Therapeutic Area: Neurology Product Name: IBC-Ab002

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Alzheimer’s Association

Deal Size: $1.0 million Upfront Cash: Undisclosed

Deal Type: Funding September 01, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY